Oncopeptides Partners with SD Pharma to Expand Pepaxti's Reach in Spain

Deal News | Jul 30, 2025 | HealthCap Venture Capital

Oncopeptides AB, a biotech company listed on Nasdaq Stockholm, has announced a strategic partnership with SD Pharma, a pharmaceutical broker in Spain. The objective is to enhance the reach of Oncopeptides' drug, Pepaxti, across Spain's hospital channels. SD Pharma will leverage its expertise in oncology and hematology to expand access to Pepaxti, which is used to treat multiple myeloma. The collaboration aims to leverage the combined efforts of Medical Science Liaisons and Regional Access Managers to improve treatment access and logistics. There will be no upfront costs for Oncopeptides, with activities beginning in Q3 2025 on a success-based model.

Sectors

Biotechnology
Pharmaceuticals
Healthcare

Geography

Spain – The partnership specifically targets the enhancement of Pepaxti's reach within the Spanish hospital system.
Sweden – Oncopeptides is a Swedish company headquartered in Stockholm, with operations including this strategic collaboration.

Industry

Biotechnology – The article involves Oncopeptides, a biotech firm focused on the research and commercialization of cancer therapies.
Pharmaceuticals – SD Pharma specializes in the commercialization of oncology and hematology products, making pharmaceuticals a relevant industry.
Healthcare – The partnership aims to enhance the distribution and access to medical treatments for cancers, directly impacting healthcare delivery.

Financials

N/A – The partnership is a success-based model with no upfront or other costs specified for Oncopeptides.

Participants

Name	Role	Type	Description
Oncopeptides AB	Target Company	Company	A Swedish biotech company focused on targeted therapies for difficult-to-treat cancers.
SD Pharma	Partner Company	Company	A Spanish pharmaceutical broker specializing in oncology and hematology.
HealthCap Venture Capital	PE Backer	Company	A venture capital firm backing Oncopeptides.